(11β,16β)-9-fluoro-17-hydroxy-16-methyl-3,20-dioxo-11-[(trimethylsilyl)oxy]pregna-1,4-dien-21-yl acetate | 64089-06-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (11β,16β)-9-fluoro-17-hydroxy-16-methyl-3,20-dioxo-11-[(trimethylsilyl)oxy]pregna-1,4-dien-21-yl acetate
• 英文别名: 11β-trimethylsiloxy-17α-hydroxy-21-acetoxy-9α-fluoro-16β-methyl-pregna-1,4-diene-3,20-dione；(11beta,16beta)-9-Fluoro-17-hydroxy-16-methyl-3,20-dioxo-11-[(trimethyl-silyl)oxy]-pregna-1,4-dien-21-yl acetate；[2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-17-hydroxy-10,13,16-trimethyl-3-oxo-11-trimethylsilyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
• CAS: 64089-06-1
• 化学式: C₂₇H₃₉FO₆Si
• 分子量: 506.687
• InChiKey: AKORXZJFSXRDHM-RJSQOEHGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.33
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  89.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (11β,16β)-9-fluoro-17-hydroxy-16-methyl-3,20-dioxo-11-[(trimethylsilyl)oxy]pregna-1,4-dien-21-yl acetate 、 异氰酸戊酯 以 甲苯 为溶剂， 反应 48.0h， 生成
  参考文献：
  名称：

  Discovery of betamethasone 17α-carbamates as dissociated glucocorticoid receptor modulators in the rat

  摘要：

  A series of betamethasone 17 alpha-carbamates were designed, synthesized, and evaluated for their ability to dissociate the two main functions of the glucocorticoid receptor, that is, transactivation and transrepression, in rat cell lines. A number of alkyl substituted betamethasone 17 alpha-carbamates were identified with excellent affinity for the glucocorticoid receptor (e.g., 7, GR IC(50) 5.1 nM) and indicated dissociated profiles in functional assays of transactivation (rat tyrosine aminotransferase, TAT, and rat glutamine synthetase, GS) and transrepression (human A549 cells, MMP-1 assay). Gratifyingly, the in-vivo profile of these compounds, for example, 7, also indicated potent anti-inflammatory activity with impaired effects on glucose, insulin, triglycerides, and body weight. Taken together, these results indicate that dissociated glucocorticoid receptor modulators can be identified in rodents. (C) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2008.07.037
• 作为产物：
  描述：

  (11β,16β)-9-fluoro-16-methyl-3,20-dioxo-11,17-bis[(trimethylsilyl)oxy]pregna-1,4-dien-21-yl acetate 在 四丁基氟化铵 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 以74%的产率得到(11β,16β)-9-fluoro-17-hydroxy-16-methyl-3,20-dioxo-11-[(trimethylsilyl)oxy]pregna-1,4-dien-21-yl acetate
  参考文献：
  名称：

  Discovery of betamethasone 17α-carbamates as dissociated glucocorticoid receptor modulators in the rat

  摘要：

  A series of betamethasone 17 alpha-carbamates were designed, synthesized, and evaluated for their ability to dissociate the two main functions of the glucocorticoid receptor, that is, transactivation and transrepression, in rat cell lines. A number of alkyl substituted betamethasone 17 alpha-carbamates were identified with excellent affinity for the glucocorticoid receptor (e.g., 7, GR IC(50) 5.1 nM) and indicated dissociated profiles in functional assays of transactivation (rat tyrosine aminotransferase, TAT, and rat glutamine synthetase, GS) and transrepression (human A549 cells, MMP-1 assay). Gratifyingly, the in-vivo profile of these compounds, for example, 7, also indicated potent anti-inflammatory activity with impaired effects on glucose, insulin, triglycerides, and body weight. Taken together, these results indicate that dissociated glucocorticoid receptor modulators can be identified in rodents. (C) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2008.07.037

文献信息

• 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
  申请人：Ali Amjad

  公开号：US20060063746A1

  公开（公告）日：2006-03-23

  The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharamaceutical compositions and methods of use are also included.

  本发明涵盖了公式（I）的化合物或其药学上可接受的盐或水合物，这些化合物可用作选择性糖皮质激素受体配体，用于治疗各种自身免疫和炎症性疾病或病况。还包括药物组合物和使用方法。